Apogee Therapeutics (APGE) announced that it has initiated dosing of healthy volunteers in its clinical trial of APG333, a novel, subcutaneous half-life extended monoclonal antibody targeting thymic stromal lymphopoietin, which is being evaluated initially as a treatment for people living with asthma, COPD and broader I&I conditions.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- Apogee Therapeutics price target raised to $90 from $87 at Wedbush
- Apogee Therapeutics Advances in I&I Disease Treatments
- Apogee Therapeutics highlights progress at 2024 Inaugural R&D Day
- Apogee Therapeutics plans to take combination approach to AD
- Apogee Therapeutics price target raised to $110 from $95 at Guggenheim